Source comparison
Modified vs Unmodified CJC-1295: DAC Alters Pharmacokinetics Entirely
The term 'CJC-1295' technically refers to two distinct compounds with overlapping names but fundamentally different pharmacokinetic profiles. CJC-1295 with DAC (drug affinity complex). The original formulation. Includes the maleimide modification that binds se
This comparison does not assign a generated winner or score.
- The term 'CJC-1295' technically refers to two distinct compounds with overlapping names but fundamentally different pharmacokinetic profiles. CJC-1295 with DAC (drug affinity complex). The original formulation. Includes the maleimide modification that binds serum albumin, extending the half-life to approximately one week. CJC-1295 without DAC. Often called Modified GRF (1-29) or Mod GRF. Lacks the albumin-binding component and has a half-life measured in minutes to hours, similar to native GHRH but with improved DPP-IV resistance due to substitutions at positions 2, 8, 15, and 27.
- The practical difference for research applications is dosing frequency and pulse pattern. Modified GRF (1-29) must be administered 1–3 times daily to maintain elevated GH levels, and its short half-life means each injection produces a discrete, pronounced GH pulse lasting 2–4 hours. This makes it ideal for research studying acute GH release dynamics, post-exercise anabolism, or circadian timing effects. CJC-1295 with DAC, by contrast, is dosed weekly or bi-weekly and produces sustained, moderate GH elevation across the entire dosing interval without sharp peaks. This suits research focused on chronic metabolic effects, body composition changes over weeks to months, or age-related GH decline where stable, long-term elevation is the target. Neither form is 'better'. They're tools for different research questions. Teams exploring acute signalling cascades downstream of GH receptor activation use Modified GRF; those studying cumulative effects on lean mass, fat oxidation, or bone density a